Poor therapeutic outcomes in KRAS-mutant non-small cell lung cancer due to chemoresistance conferred by SLC7A11
Clinical and Translational Oncology · 2024
DOI: 10.1007/s12094-024-03592-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Shiyu Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, People's Republic of China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proto-Oncogene Proteins p21(ras), Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: This study aimed to confirm whether Kirsten rat sarcoma viral oncogene (KRAS) mutations affect the therapeutic efficacy of non-small cell lung cancer (NSCLC) and, if so, to explore what the possible mechanisms might be. METHODS: We retrospectively analyzed the efficacy of immunochemotherapy in KRAS-mutant NSCLC patients compared to driver-negative patients. Online data platforms were used to find immunotherapy cases, and survival analysis compared treatments' efficacy. Cytotoxicity assays measured chemosensitivity in KRAS-mutant versus wild-type NSCLC to drugs like paclitaxel, carboplatin, and pemetrexed. Bioinformatics confirmed the KRAS-SLC7A11 link and cell experiments tested SLC7A11's role in chemoresistance. Animal studies verified the antitumor effects of SLC7A11 inhibitors with chemotherapy. RESULTS: Patients with KRAS-mutated NSCLC have a shorter therapeutic effectiveness duration with immunochemotherapy than patients with driver gene-negative status. The efficacy of immunotherapy alone is similar between the two groups. The KRAS mutation can enhance chemoresistance by upregulating SLC7A11, and inhibiting SLC7A11 can increase the sensitivity of KRAS-mutated NSCLC to chemotherapy. CONCLUSION: This study suggests that KRAS-mutant NSCLC can enhance its acquired chemoresistance by overexpressing SLC7A11, leading to poorer therapeutic outcomes. Targeting the KRAS-SLC7A11 axis could increase sensitivity to chemotherapeutic drugs, providing theoretical support for future treatment directions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, People's Republic of China.
- Department of Oncology, First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, People's Republic of China. 13605179453@126.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, S., Ge, Y., Liu, J., & Lu, K. (2024). Poor therapeutic outcomes in KRAS-mutant non-small cell lung cancer due to chemoresistance conferred by SLC7A11. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03592-4
Vancouver
Zhang S, Ge Y, Liu J, Lu K. Poor therapeutic outcomes in KRAS-mutant non-small cell lung cancer due to chemoresistance conferred by SLC7A11. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03592-4
BibTeX
@article{Zhang2024,
author = {Zhang, Shiyu and Ge, Yutong and Liu, Jingwen and Lu, Kaihua},
title = {Poor therapeutic outcomes in KRAS-mutant non-small cell lung cancer due to chemoresistance conferred by SLC7A11},
journal = {Clinical and Translational Oncology},
year = {2024},
doi = {10.1007/s12094-024-03592-4}
}
EUVIMED